{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:42:51Z","timestamp":1790473371018,"version":"4.1.0"},"reference-count":38,"publisher":"Jaypee Brothers Medical Publishing","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.59556\/japi.72.0730","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T06:52:51Z","timestamp":1750488771000},"page":"39-44","source":"Crossref","is-referenced-by-count":1,"title":["Achievement of ABC Goals in Type 2 Diabetes in Real-life"],"prefix":"10.59556","volume":"72","author":[{"given":"Hemraj Balchand","family":"Chandalia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayshri Dilip","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal Hemraj","family":"Chandalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"key":"key20250621065248_B1","doi-asserted-by":"crossref","first-page":"977\u2013","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus.","volume":"329:","author":"Diabetes Control and Complications Trial Research Group.","year":"1993;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B2","doi-asserted-by":"crossref","first-page":"381\u2013","DOI":"10.1056\/NEJM200002103420603","article-title":"Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.","volume":"342:","author":"The Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Research Group.","year":"2000;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B3","doi-asserted-by":"crossref","first-page":"2643\u2013","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.","volume":"353:","author":"The Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) Study Research Group.","year":"2005;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B4","doi-asserted-by":"crossref","first-page":"837\u2013","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).","volume":"352:","author":"UK Prospective Diabetes Study (UKPDS) Group.","year":"1998;","journal-title":"Lancet"},{"key":"key20250621065248_B5","doi-asserted-by":"crossref","first-page":"1577\u2013","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes.","volume":"359:","author":"Holman","year":"2008;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B6","doi-asserted-by":"crossref","first-page":"140\u2013","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.","volume":"38:","author":"Inzucchi","year":"2015;","journal-title":"Diabetes Care"},{"key":"key20250621065248_B7","doi-asserted-by":"crossref","first-page":"S33\u2013","DOI":"10.2337\/diacare.25.2007.S33","article-title":"Standards of medical care for patients with diabetes mellitus.","volume":"25:","author":"American Diabetes Association.","year":"2002;","journal-title":"Diabetes Care"},{"key":"key20250621065248_B8","first-page":"46.","article-title":"Controversial question: how closely is it possible to treat type 2 diabetic patients to recommended therapeutic goals in daily clinical practice?","volume":"24:","author":"Chandalia","year":"2002;","journal-title":"Medicographia"},{"issue":"(Suppl 1):","key":"key20250621065248_B9","doi-asserted-by":"crossref","first-page":"S73\u2013","DOI":"10.2337\/dc21-S006","article-title":"6. Glycemic targets: standards of medical care in diabetes\u20142021.","volume":"44","author":"American Diabetes Association.","year":"2021;","journal-title":"Diabetes Care"},{"key":"key20250621065248_B10","doi-asserted-by":"crossref","first-page":"482\u2013","DOI":"10.1016\/j.ihj.2017.10.007","article-title":"A study on the glycemic, lipid and blood pressure control among the type 2 diabetes patients of north Kerala, India.","volume":"70:","author":"Kumar","year":"2018;","journal-title":"Indian Heart J"},{"key":"key20250621065248_B11","doi-asserted-by":"crossref","first-page":"e000654.","DOI":"10.1136\/bmjdrc-2019-000654","article-title":"Real-world evidence of glycemic control among patients with type 2 diabetes mellitus in India: the TIGHT study.","volume":"7:","author":"Borgharkar","year":"2019;","journal-title":"BMJ Open Diabetes Res Care"},{"key":"key20250621065248_B12","doi-asserted-by":"crossref","first-page":"474\u2013","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17).","volume":"11:","author":"Anjana","year":"2023;","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20250621065248_B13","doi-asserted-by":"crossref","first-page":"2298\u2013","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years\u2019 follow-up on the Steno-2 randomised trial.","volume":"59:","author":"G\u00e6de","year":"2016;","journal-title":"Diabetologia"},{"key":"key20250621065248_B14","doi-asserted-by":"crossref","first-page":"2560\u2013","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.","volume":"358:","author":"The ADVANCE Collaborative Group.","year":"2008;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B15","doi-asserted-by":"crossref","first-page":"2545\u2013","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes.","volume":"358:","author":"The Action to Control Cardiovascular Risk in Diabetes Study Group.","year":"2008;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B16","doi-asserted-by":"crossref","first-page":"129\u2013","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes.","volume":"360:","author":"Duckworth","year":"2009;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B17","doi-asserted-by":"crossref","first-page":"233\u2013","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes.","volume":"363:","author":"Chew","year":"2010;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B18","doi-asserted-by":"crossref","first-page":"701\u2013","DOI":"10.2337\/dc15-2283","article-title":"Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes.","volume":"39:","author":"ACCORD Study Group.","year":"2016;","journal-title":"Diabetes Care"},{"key":"key20250621065248_B19","doi-asserted-by":"crossref","first-page":"316\u2013","DOI":"10.2337\/dc14-0920","article-title":"Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study.","volume":"38:","author":"Khunti","year":"2015;","journal-title":"Diabetes Care"},{"key":"key20250621065248_B20","doi-asserted-by":"crossref","first-page":"311\u2013","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375:","author":"Marso","year":"2016;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B21","doi-asserted-by":"crossref","first-page":"2117\u2013","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes.","volume":"373:","author":"Zinman","year":"2015;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B22","doi-asserted-by":"crossref","first-page":"644\u2013","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377:","author":"Neal","year":"2017;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B23","doi-asserted-by":"crossref","first-page":"1995\u2013","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381:","author":"McMurray","year":"2019;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B24","doi-asserted-by":"crossref","first-page":"2295\u2013","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380:","author":"Perkovic","year":"2019;","journal-title":"N Engl J Med"},{"key":"key20250621065248_B25","first-page":"1522\u2013","article-title":"Glycated hemoglobin.","volume":"83:","author":"Chandalia","year":"2002;","journal-title":"Curr Sci"},{"key":"key20250621065248_B26","doi-asserted-by":"crossref","first-page":"13.","DOI":"10.1186\/s12992-015-0098-8","article-title":"Health in the sustainable development goals: ready for a paradigm shift?","volume":"11:","author":"Buse","year":"2015;","journal-title":"Global Health"},{"key":"key20250621065248_B27","doi-asserted-by":"crossref","first-page":"275\u2013","DOI":"10.2337\/diacare.25.2.275","article-title":"Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the diabetes control and complications trial.","volume":"25:","author":"Rohlfing","year":"2002;","journal-title":"Diabetes Care"},{"key":"key20250621065248_B28","unstructured":"https:\/\/ngsp.org\/A1ceAG.asp. Accessed on Feb 14, 2024"},{"issue":"(Suppl 1):","key":"key20250621065248_B29","first-page":"1\u2013","article-title":"RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus.","volume":"42","year":"2022;","journal-title":"Int J Diabetes Dev Ctries"},{"issue":"(Supplement_1):","key":"key20250621065248_B30","doi-asserted-by":"crossref","first-page":"S90\u2013","DOI":"10.2337\/dc19-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142019.","volume":"42","author":"American Diabetes Association.","year":"2019;","journal-title":"Diabetes Care"},{"key":"key20250621065248_B31","doi-asserted-by":"crossref","first-page":"132\u2013","DOI":"10.1016\/j.mjafi.2014.10.008","article-title":"The ABC of diabetes. How many patients are able to achieve the goal laid down by American Diabetes Association?","volume":"71:","author":"Menon","year":"2015;","journal-title":"Med J Armed Forces India"},{"key":"key20250621065248_B32","doi-asserted-by":"crossref","first-page":"881\u2013","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).","volume":"26:","author":"Monnier","year":"2003;","journal-title":"Diabetes Care"},{"key":"key20250621065248_B33","doi-asserted-by":"crossref","first-page":"e000354.","DOI":"10.1136\/bmjdrc-2016-000354","article-title":"Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes.","volume":"5:","author":"Snorgaard","year":"2017;","journal-title":"BMJ Open Diabetes Res Care"},{"key":"key20250621065248_B34","doi-asserted-by":"crossref","first-page":"359\u2013","DOI":"10.1007\/s13410-016-0467-8","article-title":"Glycemic targets in diabetes.","volume":"36:","author":"Chandalia","year":"2016;","journal-title":"Int J Diabetes Dev Ctries"},{"key":"key20250621065248_B35","doi-asserted-by":"crossref","first-page":"100498.","DOI":"10.1016\/j.obmed.2023.100498","article-title":"The trend of achieving ABC goals in patients with type 2 diabetes between 2010\u20132014 and 2015\u20132019.","volume":"41:","author":"Tavakoli","year":"2023;","journal-title":"Obes Med"},{"key":"key20250621065248_B36","doi-asserted-by":"crossref","first-page":"189\u2013","DOI":"10.2337\/diacare.1.3.189","article-title":"Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness.","volume":"1:","author":"Lebovitz","year":"1978;","journal-title":"Diabetes Care"},{"key":"key20250621065248_B37","doi-asserted-by":"crossref","first-page":"2461\u2013","DOI":"10.1007\/s00125-018-4729-5","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","volume":"61:","author":"Davies","year":"2018;","journal-title":"Diabetologia"},{"key":"key20250621065248_B38","doi-asserted-by":"crossref","first-page":"387\u2013","DOI":"10.1007\/s11606-015-3556-3","article-title":"Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events.","volume":"31:","author":"Rana","year":"2016;","journal-title":"J Gen Intern Med"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T06:52:59Z","timestamp":1750488779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-72-11-39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.59556\/japi.72.0730"],"URL":"https:\/\/doi.org\/10.59556\/japi.72.0730","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}